LIXTE-logo-web-horz-black-190LIXTE-logo-web-horz-black-190LIXTE-logo-web-horz-black-190LIXTE-logo-web-horz-black-190
  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Articles
  • Podcast
  • Video
  • All
  • All
  • lixte-biotech
June 26, 2024
Article: A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm
Published by lixte-biotech on June 26, 2024
Categories
  • Articles

Article: A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm

By Mary C. Clark, Rongze Olivia Lu, Winson S. Ho, Matheus Henrique Dias, René Bernards, […]
Do you like it?
Read more
June 10, 2024
Cancer Cell Cover
Published by lixte-biotech on June 10, 2024
Categories
  • Articles

Article: The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy in Cancer Cell

By Matheus Henrique Dias, Chrysa Papagianni, Rene Bernards Volume 42, Issue 6, 10 June 2024, […]
Do you like it?
Read more
May 1, 2024
MedInvest Biotech and Pharma Conference Presentation
Published by lixte-biotech on May 1, 2024
Categories
  • Video

Video: MedInvest Biotech and Pharma Conference Presentation

Lixte’s CEO Bas van der Baan presented at MedInvest Biotech and Pharma Conference, April 3-4, […]
Do you like it?
Read more
April 30, 2024
Published by lixte-biotech on April 30, 2024
Categories
  • Articles

Article: Too much of a good thing in Nature Reviews Cancer

Research Highlight | Published: 30 April 2024 Targeted Therapies | By Anna Dart   Many […]
Do you like it?
Read more
April 11, 2024
First in Human Episode #59 featuring Bas van der Baan
Published by lixte-biotech on April 11, 2024
Categories
  • Podcast

Podcast: First in Human Episode #59 featuring Bas van der Baan

First in Human Episode #59 featuring Bas van der Baan Join as we dive deep […]
Do you like it?
Read more
March 20, 2024
Update on Progress with Proprietary LB-100 Compound
Published by lixte-biotech on March 20, 2024
Categories
  • Video

Video: Update on Progress with Proprietary LB-100 Compound

LIXTE Biotechnology Holdings Provides Update on Progress with Proprietary LB-100 Compound to Enhance Chemotherapy and […]
Do you like it?
Read more
February 5, 2024
Matheus Dos Santos Dias, a researcher at the Netherlands Cancer Institute. He is working on a Lixte drug.
Published by lixte-biotech on February 5, 2024
Categories
  • Articles

Article: LOS ANGELES BUSINESS JOURNAL: Lixte CEO Takes On a New Course

Pasadena-based pharmaceutical company Lixte Biotechnology Holdings Inc.’s new chief executive is also charting a new […]
Do you like it?
Read more
December 21, 2023
Developing the drug LB-100 to inhibit PP2A
Published by lixte-biotech on December 21, 2023
Categories
  • Video

Video: Developing the drug LB-100 to inhibit PP2A

Researchers at the National Institute of Health as well as the Netherlands Cancer Institute and […]
Do you like it?
Read more

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company developing innovative cancer therapies and oncology treatments using PP2A inhibition with LB-100.

CONTACT

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
Email: info@lixte.com

LIXTE Biotechnology Holdings, Inc.
is publicly traded as LIXT.

Privacy Policy | Terms of Use

  • Our Approach
  • Science
  • Programs
  • Team
  • Investor Information
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
© 2024 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. | Site by Third Eye Industries